Insys Therapeutics Inc (INSY) Expected to Announce Quarterly Sales of $32.27 Million

Equities analysts expect Insys Therapeutics Inc (NASDAQ:INSY) to announce $32.27 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Insys Therapeutics’ earnings. The lowest sales estimate is $30.82 million and the highest is $34.00 million. Insys Therapeutics posted sales of $54.86 million in the same quarter last year, which would indicate a negative year over year growth rate of 41.2%. The firm is scheduled to issue its next quarterly earnings results on Monday, April 2nd.

On average, analysts expect that Insys Therapeutics will report full-year sales of $32.27 million for the current financial year, with estimates ranging from $140.03 million to $150.90 million. For the next financial year, analysts expect that the firm will report sales of $161.19 million per share, with estimates ranging from $141.00 million to $186.13 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that that provide coverage for Insys Therapeutics.

A number of equities analysts have recently commented on INSY shares. Oppenheimer restated a “hold” rating on shares of Insys Therapeutics in a report on Monday, October 30th. Zacks Investment Research downgraded Insys Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. Jefferies Group lowered their target price on Insys Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 3rd. ValuEngine upgraded Insys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 29th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $14.00 target price on shares of Insys Therapeutics in a research note on Wednesday, October 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $9.38.

Shares of Insys Therapeutics (NASDAQ INSY) opened at $13.38 on Thursday. Insys Therapeutics has a 12-month low of $4.10 and a 12-month high of $15.02. The stock has a market capitalization of $845.34, a price-to-earnings ratio of -5.25 and a beta of 0.76.

Several hedge funds and other institutional investors have recently made changes to their positions in INSY. Dynamic Technology Lab Private Ltd bought a new stake in Insys Therapeutics during the 3rd quarter valued at $119,000. Janney Montgomery Scott LLC bought a new stake in Insys Therapeutics during the 3rd quarter valued at $135,000. SG Americas Securities LLC bought a new stake in Insys Therapeutics during the 2nd quarter valued at $138,000. Voya Investment Management LLC bought a new stake in Insys Therapeutics during the 2nd quarter valued at $149,000. Finally, BNP Paribas Arbitrage SA raised its stake in Insys Therapeutics by 213.2% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,133 shares of the specialty pharmaceutical company’s stock valued at $166,000 after acquiring an additional 8,940 shares in the last quarter. 25.60% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Insys Therapeutics Inc (INSY) Expected to Announce Quarterly Sales of $32.27 Million” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/01/04/insys-therapeutics-inc-insy-expected-to-announce-quarterly-sales-of-32-27-million.html.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Get a free copy of the Zacks research report on Insys Therapeutics (INSY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply